Literature DB >> 11672871

Biodegradable microspheres for vitreoretinal drug delivery.

R Herrero-Vanrell1, M F Refojo.   

Abstract

Vitreoretinal disorders are one of the major causes of blindness in the developed world. Treatments of these pathologies often include repeated intravitreous injections to achieve intraocular drug levels within the therapeutical range. However, the risks of complications increase with the frequency of intravitreous injections. Controlled drug delivery formulations, offer an excellent alternative to multiple administrations. These systems are capable of delivering drugs over longer time periods than conventional formulations. Currently, several kinds of polymer devices for drug delivery to the posterior segment of the eye are under clinical use, or under investigation. Among these devices, microparticulates, such as microspheres, provide an alternative to multiple injections to obtain sustained release of the drug with a single administration. Among the polymers used to make the injectable microparticles, the most commonly used are poly(lactic acid), poly(glycolic acid) and copolymers of lactic and glycolic acids because they are biocompatible and degrade to metabolic products that are easily eliminated from the body. This article reviews the literature of biodegradable polymeric microspheres loaded with drugs, that have been investigated for delivery by intravitreous injection to treat diverse vitreoretinal diseases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11672871     DOI: 10.1016/s0169-409x(01)00200-9

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  33 in total

Review 1.  Strategies to influence PVR development.

Authors:  Bernd Kirchhof
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-08-10       Impact factor: 3.117

2.  Diffusion Regulation in the Vitreous Humor.

Authors:  Benjamin Tillmann Käsdorf; Fabienna Arends; Oliver Lieleg
Journal:  Biophys J       Date:  2015-11-17       Impact factor: 4.033

3.  In vitro, in vivo, and in silico evaluation of the bioresponsive behavior of an intelligent intraocular implant.

Authors:  Lisa C du Toit; Trevor Carmichael; Thirumala Govender; Pradeep Kumar; Yahya E Choonara; Viness Pillay
Journal:  Pharm Res       Date:  2013-09-04       Impact factor: 4.200

4.  Impacts of nanomedicines in ocular pharmacotherapy.

Authors:  Ailar Nakhlband; Jaleh Barar
Journal:  Bioimpacts       Date:  2011-06-09

Review 5.  Emerging Concepts in the Treatment of Diabetic Retinopathy.

Authors:  Michael Patrick Ellis; Daniella Lent-Schochet; Therlinder Lo; Glenn Yiu
Journal:  Curr Diab Rep       Date:  2019-11-20       Impact factor: 4.810

6.  Development of sustained-release microspheres for the delivery of SAR 1118, an LFA-1 antagonist intended for the treatment of vascular complications of the eye.

Authors:  Sarath Yandrapu; Uday B Kompella
Journal:  J Ocul Pharmacol Ther       Date:  2012-12-20       Impact factor: 2.671

Review 7.  Intraocular sustained-release delivery systems for triamcinolone acetonide.

Authors:  Saffar Mansoor; Baruch D Kuppermann; M Cristina Kenney
Journal:  Pharm Res       Date:  2009-01-28       Impact factor: 4.200

8.  The visualisation of vitreous using surface modified poly(lactic-co-glycolic acid) microparticles.

Authors:  David Y S Chau; Naing L Tint; Russell J Collighan; Martin Griffin; Harminder S Dua; Kevin M Shakesheff; Felicity R A J Rose
Journal:  Br J Ophthalmol       Date:  2010-05       Impact factor: 4.638

9.  Intravitreal Poly(L-lactide) Microparticles Sustain Retinal and Choroidal Delivery of TG-0054, a Hydrophilic Drug Intended for Neovascular Diseases.

Authors:  Namdev B Shelke; Rajendra Kadam; Puneet Tyagi; Vidhya R Rao; Uday B Kompella
Journal:  Drug Deliv Transl Res       Date:  2011-02       Impact factor: 4.617

10.  Evaluations of therapeutic efficacy of intravitreal injected polylactic-glycolic acid microspheres loaded with triamcinolone acetonide on a rabbit model of uveitis.

Authors:  Wenchang Li; Bing He; Wenbing Dai; Qiang Zhang; Yuling Liu
Journal:  Int Ophthalmol       Date:  2013-07-19       Impact factor: 2.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.